TGV-inhalonix To Report New Data on Breakthrough Drug for Cystic Fibrosis at the Largest Conference of the Year

  ORLANDO, FL - 10/27/2016 (PRESS RELEASE JET)

TGV-inhalonix, a New York-based pharmaceutical company with extensive experience developing  novel anti-infective agents, announced that it will present new findings on Mul-1867, its novel drug candidate, the first to have overcome antibiotic resistance of bacterial and fungal pathogens causing lung infections, at the world’s most significant gathering on cystic fibrosis - 30th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, October 27-29, 2016.

NACFC is the most important US conference of its kind and is organized by Cystic Fibrosis Foundation - the world leader in the search for a cure for cystic fibrosis.  Cystic Fibrosis is a progressive, genetic disease that causes mucus buildup, clogs the airways and traps bacteria, leading to infections, extensive lung damage and, eventually, respiratory failure.  The median predicted survival age in persons with cystic fibrosis in the United States is 39.3 years and the disease remains an ongoing battle.

At the upcoming Cystic Fibrosis Conference, TGV-inhalonix will report new data for efficacy of Mul-1867 against extremely virulent mixed bacterial-fungal infections affecting most patients with cystic fibrosis.  These infections have consistently proven to be resistant to antibiotic treatment and cause fast lung function decline.  Mul-1867 – a breakthrough drug - will change the landscape dramatically. 

Mul-1867 has already shown promising efficacy in human studies outside the U.S. The U.S. Food and Drug Administration earlier this year granted Mul-1867 Orphan Drug Designation based on early indications of its potential for fighting lung infections in cystic fibrosis patients. The special status is intended to provide incentives for the development of drugs and biologics to treat rare diseases.

“There are a number of new drugs being tested to fight the chronic lung infections that plague cystic fibrosis patients, but Mul-1867 is the first drug candidate under development that holds promise against multiple strains of bacteria, as well those infections caused by a mix of bacteria and fungi,” said George Tetz, leader of research and development at TGV-Inhalonix.

Following presentations on the effectiveness of its inhaled antimicrobial, Mul-1867, at the European Cystic Fibrosis Conference and ASM Microbe 2016, TGV-inhalonix researchers Victor and George Tetz said they expect to have the drug in clinical studies in the U.S. within two years.

The Cystic Fibrosis Foundation funds more CF research than any other organization and states that nearly every CF drug available today was made possible because of the Foundation support.

For more information about George and Victor Tetz and TGV-inhalonix, please contact Max Smetannikov (MVG) at +1.212.330.8063 ext. 1001, info@mvgmain.com